FDA to Remove Black Box Warning from Three Estrogen Patch Products

The U.S. health department is set to remove the broad black box warning from three estrogen patch products. This regulatory action by the FDA signifies a re-evaluation of the safety profile for these specific medications, potentially impacting patient access and prescribing practices.